Oyster Point Pharma Announces Clinical Data Presentation of OC-01 (varenicline) Nasal Spray for Dry Eye Disease at the Association for Research in Vision and Ophthalmology 2021 Virtual Annual Meeting
May 01, 2021 08:00 ET
|
Oyster Point Pharma, Inc.
PRINCETON, N.J., May 01, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
Oyster Point Pharma to Report First Quarter 2021 Financial Results on May 6, 2021
April 30, 2021 08:00 ET
|
Oyster Point Pharma, Inc.
PRINCETON, N.J., April 30, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization...
Oyster Point Pharma Announces New Appointment to Board of Directors
April 05, 2021 06:00 ET
|
Oyster Point Pharma, Inc.
PRINCETON, N.J., April 05, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization...
Oyster Point Pharma Announces FDA Acceptance for Filing New Drug Application for OC-01 (varenicline) Nasal Spray for the Treatment of Signs and Symptoms of Dry Eye Disease
March 02, 2021 06:00 ET
|
Oyster Point Pharma, Inc.
Prescription Drug User Fee Act (PDUFA) target action date is October 17, 2021U.S. Food and Drug Administration (FDA) has stated that it does not intend to hold an advisory committee meeting to discuss...
Oyster Point Pharma to Participate in the 41st Annual Cowen Healthcare Conference
February 25, 2021 16:01 ET
|
Oyster Point Pharma, Inc.
PRINCETON, N.J., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
Oyster Point Pharma Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights
February 18, 2021 16:01 ET
|
Oyster Point Pharma, Inc.
OC-01 (Varenicline) Nasal Spray New Drug Application (NDA) Submitted to the U.S. Food and Drug Administration (FDA) for the Treatment of Signs and Symptoms of Dry Eye Disease on December 17, 2020Phase...
Oyster Point Pharma to Report Fourth Quarter and Full Year 2020 Financial Results on February 18, 2021
February 12, 2021 09:14 ET
|
Oyster Point Pharma, Inc.
PRINCETON, N.J., Feb. 12, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
Oyster Point Pharma to Participate in the 39th Annual J.P. Morgan Healthcare Conference
December 29, 2020 16:01 ET
|
Oyster Point Pharma, Inc.
PRINCETON, N.J., Dec. 29, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
Oyster Point Pharma Submits New Drug Application to the U.S. Food and Drug Administration for OC-01 (varenicline) Nasal Spray for the Treatment of Signs and Symptoms of Dry Eye Disease
December 18, 2020 07:00 ET
|
Oyster Point Pharma, Inc.
PRINCETON, N.J., Dec. 18, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
Oyster Point Pharma Strengthens Executive Leadership Team with the Appointment of Chief Medical and Chief Scientific Officers
December 07, 2020 07:00 ET
|
Oyster Point Pharma, Inc.
PRINCETON, N.J., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...